Turned Up to Eleven
Visceral hypersensitivity — an enhanced perception of stimuli arising from the internal organs — is one of the most consistently demonstrated mechanisms in irritable bowel syndrome and other disorders of gut-brain interaction. In balloon distension studies, where a small balloon is inflated in the rectum or colon, IBS patients report pain and discomfort at volumes and pressures that healthy controls perceive as merely fullness or no sensation at all.
This is not about exaggeration or malingering. Functional brain imaging (fMRI) studies show that IBS patients exhibit genuinely increased activation of the anterior cingulate cortex, insula, prefrontal cortex, and thalamus in response to the same level of colonic distension. The brain is receiving a normal signal from the gut and processing it as threatening.
Peripheral Sensitisation
The amplification can begin in the gut wall itself. Post-infectious IBS — which develops in 10 to 15 percent of patients after acute gastroenteritis — provides the clearest model. After the acute infection resolves, subtle mucosal changes persist: increased mast cells in close proximity to nerve endings, elevated serotonin (5-HT) release from enterochromaffin cells, and upregulated nerve growth factor (NGF) expression. Mast cell mediators — histamine, tryptase, prostaglandins — directly sensitise visceral afferent nerve endings, lowering their activation threshold.
This mast cell-nerve proximity has been quantified: in IBS patients, the distance between mast cells and enteric nerve fibres is significantly reduced compared to healthy controls, and the degree of proximity correlates with symptom severity and abdominal pain intensity.
Central Sensitisation
Peripheral signals converge on the dorsal horn of the spinal cord, where repeated stimulation can induce central sensitisation — a form of neural plasticity where spinal cord neurons become hyperexcitable. Wind-up phenomena and expansion of receptive fields mean that progressively less peripheral input is needed to trigger pain signals ascending to the brain.
At the brain level, dysfunction in descending inhibitory pathways — the body's built-in pain suppression system, operating through serotonergic and noradrenergic neurons from the brainstem — fails to dampen the amplified signals. Stress exacerbates this through corticotropin-releasing factor (CRF), which increases colonic motility, mast cell degranulation, and pain perception simultaneously.
Therapeutic Implications
Targeting visceral hypersensitivity requires addressing both peripheral and central components. Peripherally, mast cell stabilisers (ketotifen, ebastine), 5-HT3 antagonists (alosetron, ondansetron), and anti-inflammatory approaches aim to reduce afferent sensitisation. Centrally, low-dose tricyclic antidepressants (amitriptyline, nortriptyline) and serotonin-noradrenaline reuptake inhibitors (duloxetine) enhance descending inhibition and have proven visceral analgesic properties independent of their antidepressant effects.
Gut-directed hypnotherapy, which modifies central pain processing through suggestion and relaxation, reduces visceral hypersensitivity on balloon distension testing — providing objective evidence that the intervention alters nerve signalling, not just perception. It remains one of the most effective treatments for refractory IBS.